文献速递肿瘤 PET/CT放射性药物与辐射防护

近期嵌合抗原受体T细胞治疗后新发结核病干扰FDG PET/CT评估

New Onset of Tuberculosis Complicating FDG PET/CT Evaluation in Patient With Recent Chimeric Antigen Receptor T-Cell Therapy.
PubMed 文献 · Clin Nucl Med · 2023-04-16

一名16岁少女因急性淋巴细胞白血病接受CD19嵌合抗原受体(CAR)T细胞治疗,出现新发发热。CAR-T后1个月和2个月的18F-FDG PET/CT均显示纵隔淋巴结异常活性灶,而治疗前检查未见。这些异常活性灶后来证实为CAR-T后新发结核病所致。

要点

  • CAR-T后新发发热患者中,FDG PET/CT纵隔淋巴结异常活性灶需鉴别感染与新发病变。
  • 本例CAR-T后1个月和2个月FDG PET/CT纵隔淋巴结异常活性灶最终证实为新发结核。
  • CAR-T治疗后新发结核可表现为FDG高摄取淋巴结,干扰肿瘤评估。

核心结论

  • CAR-T治疗后新发结核可表现为纵隔淋巴结FDG异常活性灶,干扰PET/CT评估。

研究设计与样本

  • 病例报告:一名16岁少女因急性淋巴细胞白血病接受CD19 CAR-T细胞治疗。

主要发现

  • 患者CAR-T后出现新发发热,CAR-T后1个月和2个月18F-FDG PET/CT显示纵隔淋巴结异常活性灶,治疗前检查未见。
  • 上述纵隔淋巴结异常活性灶后来证实为CAR-T后新发结核病所致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 16-year-old adolescent girl with CD19 chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia experienced new onset of the fever. 18 F-FDG PET/CT studies acquired at 1 and 2 months, respectively, after CAR-T, showed foci of abnormal activity in the mediastinal lymph nodes not seen on the study before therapy. However, these foci of abnormal activity were later proven due to newly developed tuberculosis after CAR T-cell therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang G, Yang X, Wang H, et al. New Onset of Tuberculosis Complicating FDG PET/CT Evaluation in Patient With Recent Chimeric Antigen Receptor T-Cell Therapy. Clin Nucl Med. 2023. PMID: 37083630. doi:10.1097/RLU.0000000000004655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。